Kidney Res Clin Pract.  2020 Mar;39(1):32-39. 10.23876/j.krcp.20.012.

Metformin treatment for patients with diabetes and chronic kidney disease: A Korean Diabetes Association and Korean Society of Nephrology consensus statement

• Hur KY
• Kim MK
• Ko SH
• Han M
• Lee DW
• Kwon HS
• Committee of Clinical Practice Guidelines
• Korean Diabetes Association and Committee of the Cooperative Studies
• Korean Society of Nephrology

• KMID: 2503737
• DOI: http://doi.org/10.23876/j.krcp.20.012

Abstract

The safety of metformin use for patients with type 2 diabetes mellitus (T2DM) and advanced kidney disease is controversial, and more recent guidelines have suggested that metformin be used cautiously in this group until more definitive evidence concerning its safety is available. The Korean Diabetes Association and the Korean Society of Nephrology have agreed on consensus statements concerning metformin use for patients with T2DM and renal dysfunction, particularly when these patients undergo imaging studies using iodinated contrast media (ICM). Metformin can be used safely when the estimated glomerular filtration rate (eGFR) is ≥ 45 mL/min/1.73 m². If the eGFR is between 30 and 44 mL/min/1.73 m², metformin treatment should not be started. If metformin is already in use, a daily dose of ≤ 1,000 mg is recommended. Metformin is contraindicated when the eGFR is < 30 mL/min/1.73 m². Renal function should be evaluated prior to any ICM-related procedures. During procedures involving intravenous administration of ICM, metformin should be discontinued starting the day of the procedures and up to 48 hours postprocedures if the eGFR is < 60 mL/min/1.73 m².

Keyword

Contrast media; Diabetes mellitus; Metformin; Renal insufficiency